MedTrace Logo

Cluster Randomized Trial of Hospitals to Assess Impact of Targeted Versus Universal Strategies to Reduce Methicillin-resistant Staphylococcus Aureus (MRSA) in Intensive Care Units (ICUs)

NCT00980980 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 74256

Last updated 2017-05-02

Study results available
· View outcomes & findings →

Summary

The Randomized Evaluation of Decolonization versus Universal Clearance to Eliminate MRSA (REDUCE MRSA) Trial is a cluster randomized trial of the comparative effectiveness of three strategies to prevent methicillin-resistant Staphylococcus aureus (MRSA) in intensive care units. The three strategies to be evaluated are:

* screening on admission followed by isolation of MRSA+ patients
* screening on admission followed by isolation and decolonization of MRSA+ patients
* universal decolonization on admission with no screening. The decolonization regimen involves bathing with chlorhexidine plus intra-nasal application of mupirocin. The main outcome will be MRSA+ clinical cultures.

The study is a partnership between the CDC, the CDC Prevention Epicenters, and the Hospital Corporation of America.

Conditions

  • Methicillin-resistant Staphylococcus Aureus

Interventions

DRUG

Chlorhexidine bath and nasal mupirocin

The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US - a combination of daily baths with 2% chlorhexidine cloths , plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)

Sponsors & Collaborators

  • Agency for Healthcare Research and Quality (AHRQ)

    collaborator FED

  • Centers for Disease Control and Prevention

    collaborator FED

  • Hospital Corporation of America

    collaborator INDUSTRY

  • University of California, Irvine

    collaborator OTHER

  • Department of Population Medicine, Harvard Medical School / Harvard Pilgrim Healthcare Institute

    collaborator UNKNOWN

  • Harvard Pilgrim Health Care

    lead OTHER

Principal Investigators

  • Richard Platt, MD, MS · Department of Population Medicine, Harvard Medical School / Harvard Pilgrim Healthcare Institute

  • Edward Septimus, MD · Hospital Corporation of America

  • Susan Huang, MD MPH · University of California, Irvine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00980980 on ClinicalTrials.gov